AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10717746 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin alone (150-200 micrograms/kg)
Number of subjects: 63
Study 10717746 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole alone (400 mg)
Number of subjects: 63
Study 10717746 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ivermectin and albendazole
Number of subjects: 63
Study 10717746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 7854485 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic needle (pencil point, 22 gauge)
Number of subjects: 100
Study 7854485 — intervention group
Group type: COMPARATOR
Intervention: Standard needle (20 gauge)
Number of subjects: 100
Study 1787609 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF (cyclophosphamide, doxorubicin and 5‐fluorouracil)
Number of subjects: 69
Study 1787609 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate and 5‐fluorouracil)
Number of subjects: 69
Study 7019839 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (250 mg fast release)
Number of subjects: 21
Study 7019839 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (2.5 mg)
Number of subjects: 21
Study 7019839 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Theophylline and Terbutaline
Number of subjects: 21
Study 7019839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 7019839 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 21
Study 7019839 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 21
Study 7019839 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline or Terbutaline (alone or in combination)
Number of subjects: 21
Study 30456780 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoxyderm™
Number of subjects: 7
Study 30456780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 28074556 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole (therapeutic or supratherapeutic doses daily for 11 days after a 2-day loading dose)
Number of subjects: 161
Study 28074556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 28074556 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg q.d.)
Number of subjects: 161
Study 28074556 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole (in phase III SECURE trial, n=257)
Number of subjects: 161
Study 26621254 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy with cisplatin and 9 l of saline solution during hydration in the first, fourth, and seventh week
Number of subjects: 38
Study 26621254 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving radiotherapy only
Number of subjects: 38
Study 22521701 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Veneer (RV) on Dentine (D)
Number of subjects: 135
Study 22521701 — intervention group
Group type: EXPERIMENTAL
Intervention: Variolink II (V2) on Dentine (D)
Number of subjects: 135
Study 22521701 — intervention group
Group type: EXPERIMENTAL
Intervention: Variolink Veneer (VV) on Dentine (D)
Number of subjects: 135
Study 22521701 — intervention group
Group type: EXPERIMENTAL
Intervention: Variolink Veneer (VV) on Enamel (E)
Number of subjects: 135
Study 21135055 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose platinum-based chemotherapy (HD-PB)
Number of subjects: 230
Study 21135055 — intervention group
Group type: COMPARATOR
Intervention: Conventional anthracycline-based chemotherapy
Number of subjects: 230
Study 21135055 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 230
Study 21135055 — intervention group
Group type: EXPERIMENTAL
Intervention: BRCA1-like(CGH) tumours
Number of subjects: 230
Study 19922250 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp acupuncture (SA) at left Sishencong (HN1), GB18, GB9, TH20 for 20 minutes
Number of subjects: 10
Study 19922250 — intervention group
Group type: COMPARATOR
Intervention: Upper and lower limb acupuncture (ULLA) at right LI1, LI10, LV3, ST36 for 20 minutes
Number of subjects: 10
Study 17089581 — intervention group
Group type: EXPERIMENTAL
Intervention: Two units of freshly collected cord blood transfusion
Number of subjects: 39
Study 17089581 — intervention group
Group type: COMPARATOR
Intervention: Two units of adult blood transfusion
Number of subjects: 39
Study 17089581 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria assessment after one month of treatment
Number of subjects: 39
Study 15587750 — intervention group
Group type: EXPERIMENTAL
Intervention: Right internal jugular group (G-RIJV)
Number of subjects: 272
Study 15587750 — intervention group
Group type: EXPERIMENTAL
Intervention: Left subclavian group (G-LSCV)
Number of subjects: 272
Study 15587750 — intervention group
Group type: COMPARATOR
Intervention: Right subclavian group (G-RSCV)
Number of subjects: 272
Study 15587750 — intervention group
Group type: EXPERIMENTAL
Intervention: Left internal jugular vein group (G-LIJV)
Number of subjects: 272
Study 11777489 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel (75 microg/day)
Number of subjects: 81
Study 11777489 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel (30 microg/day)
Number of subjects: 81
Study 9258415 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone replacement therapy (0.125 IU/kg per week for the first 4 weeks, then 0.25 IU/kg per week)
Number of subjects: 18
Study 9258415 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone replacement therapy
Number of subjects: 18
Study 9258415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8276025 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion at 5-15 micrograms/kg per min
Number of subjects: 40
Study 8276025 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine infusion at 5-15 micrograms/kg per min
Number of subjects: 40
Study 3106656 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide, 20 mg/d (plus insulin)
Number of subjects: 16
Study 3106656 — intervention group
Group type: COMPARATOR
Intervention: Placebo (plus insulin)
Number of subjects: 16
Study 30553231 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice (500 mL/d)
Number of subjects: 41
Study 30553231 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual diet)
Number of subjects: 41
Study 28986984 — intervention group
Group type: EXPERIMENTAL
Intervention: Component-resolved diagnosis (CRD) combined with clinical factors and sensitization patterns
Number of subjects: 423
Study 28986984 — intervention group
Group type: EXPERIMENTAL
Intervention: Cor a 9 and Cor a 14 IgE levels
Number of subjects: 423
Study 28986984 — intervention group
Group type: EXPERIMENTAL
Intervention: Cor a 1 IgE levels
Number of subjects: 423
Study 28986984 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Cor a 1 and Cor a 9
Number of subjects: 423
Study 28986984 — intervention group
Group type: EXPERIMENTAL
Intervention: Model using atopic dermatitis, pollen allergy, IgE against Cor a 14, and walnut
Number of subjects: 423
Study 28986984 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported symptoms
Number of subjects: 423
Study 27733375 — intervention group
Group type: EXPERIMENTAL
Intervention: Three preoperative cycles of epirubicin 120 mg/m2 and ifosfamide 9 g/m2 (Arm A)
Number of subjects: 328
Study 27733375 — intervention group
Group type: COMPARATOR
Intervention: Five cycles of adjuvant chemotherapy (Arm B)
Number of subjects: 328
Study 27733375 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group (both arms combined)
Number of subjects: 328
Study 27733375 — intervention group
Group type: EXPERIMENTAL
Intervention: Three cycles of chemotherapy (Arm A)
Number of subjects: 328
Study 27733375 — intervention group
Group type: COMPARATOR
Intervention: Five cycles of chemotherapy (Arm B)
Number of subjects: 328
Study 27733375 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to therapy
Number of subjects: 328
Study 24946783 — intervention group
Group type: EXPERIMENTAL
Intervention: TimeSlips creative storytelling program
Number of subjects: 10
Study 21504479 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading group
Number of subjects: 36
Study 21504479 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading group
Number of subjects: 36
Study 21504479 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 20827218 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-delivered HIV prevention training intervention
Number of subjects: 386
Study 20827218 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 386
Study 17042774 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine (Group A)
Number of subjects: 16
Study 17042774 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone (Group B)
Number of subjects: 16
Study 17042774 — intervention group
Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 16
Study 15749318 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterillium applied for 3 min
Number of subjects: 2
Study 15749318 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterillium applied for 2 min
Number of subjects: 2
Study 15749318 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterillium applied for 1.5 min
Number of subjects: 2
Study 15749318 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterillium applied for 1 min
Number of subjects: 2
Study 15749318 — intervention group
Group type: EXPERIMENTAL
Intervention: Other preparations applied for 1 min
Number of subjects: 2
Study 15749318 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterillium applied for 1.5 min (2 x 3 mL)
Number of subjects: 2
Study 11867404 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine‐15 group (3 mL of 1.5% lidocaine containing 15 microg epinephrine)
Number of subjects: 80
Study 11867404 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine‐10 group (2 mL of test dose)
Number of subjects: 80
Study 11867404 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine‐5 group (1 mL of test dose)
Number of subjects: 80
Study 11867404 — intervention group
Group type: COMPARATOR
Intervention: Saline group (3 mL of normal saline IV)
Number of subjects: 80
Study 10468074 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0
Study 10468074 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 0
Study 10468074 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 0
Study 10468074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7781586 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 25 mg at a daily dosage of 100 mg t.i.d. (25 mg - 25 mg - 50 mg)
Number of subjects: 0
Study 7781586 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 1 mg at a daily dosage of 4 mg t.i.d. (1 mg - 1 mg - 2 mg)
Number of subjects: 0
Study 7781586 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine and Lorazepam (both groups)
Number of subjects: 0
Study 2235209 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized ribavirin
Number of subjects: 150
Study 2235209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 361067 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 88
Study 361067 — intervention group
Group type: COMPARATOR
Intervention: Ethanol
Number of subjects: 88
Study 31475652 — intervention group
Group type: EXPERIMENTAL
Intervention: β-carotene supplementation
Number of subjects: 290
Study 31475652 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age at delivery
Number of subjects: 290
Study 31475652 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric measures
Number of subjects: 290
Study 31475652 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal variation
Number of subjects: 290
Study 31301621 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported self-help preventive cognitive therapy (S-PCT)
Number of subjects: 248
Study 31301621 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 248
Study 28550023 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH 75 IU
Number of subjects: 732
Study 28550023 — intervention group
Group type: COMPARATOR
Intervention: CC 100 mg
Number of subjects: 732
Study 24691248 — intervention group
Group type: EXPERIMENTAL
Intervention: Pursed-lip breathing (PLB)
Number of subjects: 40
Study 24691248 — intervention group
Group type: COMPARATOR
Intervention: Control breathing (CB)
Number of subjects: 40
Study 23363494 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary perfusion with oxygenated blood
Number of subjects: 90
Study 23363494 — intervention group
Group type: EXPERIMENTAL
Intervention: Custodiol HTK solution
Number of subjects: 90
Study 23363494 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study 21809048 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-session telephone-delivered motivational interviewing (MI)
Number of subjects: 0
Study 21809048 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-session telephone-delivered motivational interviewing (MI)
Number of subjects: 0
Study 21809048 — intervention group
Group type: COMPARATOR
Intervention: Control (no MI)
Number of subjects: 0
Study 19748405 — intervention group
Group type: EXPERIMENTAL
Intervention: Local manipulative therapy combined with exercise and soft tissue treatment
Number of subjects: 31
Study 19748405 — intervention group
Group type: EXPERIMENTAL
Intervention: Full kinetic chain manipulative therapy combined with exercise and soft tissue treatment
Number of subjects: 31
Study 15627856 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Dynamic Therapy (BDT)
Number of subjects: 30
Study 15627856 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Supportive Psychotherapy (BSP)
Number of subjects: 30
Study 15627856 — intervention group
Group type: COMPARATOR
Intervention: Waiting List Condition
Number of subjects: 30
Study 12118806 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow load amiodarone (7 g oral amiodarone more than 10 days starting 5 days before OHS; n = 56)
Number of subjects: 220
Study 12118806 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast load amiodarone (6 g oral amiodarone more than 6 days starting 1 day before OHS; n = 64)
Number of subjects: 220
Study 12118806 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 100)
Number of subjects: 220
Study 10403145 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day for first 6 weeks, adjusted to 20-50 mg/day thereafter)
Number of subjects: 203
Study 10403145 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 mg/day for first 6 weeks, adjusted to 20-80 mg/day thereafter)
Number of subjects: 203
Study 10403145 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 203
Study 10403145 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 203
Study 10403145 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 203
Study 7585063 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 2
Study 7585063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 2129373 — intervention group
Group type: EXPERIMENTAL
Intervention: TPA (tissue plasminogen activator)
Number of subjects: 0
Study 2129373 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate PTCA (percutaneous transluminal coronary angioplasty)
Number of subjects: 0
Study 2129373 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine interventional post-lytic care (PTCA)
Number of subjects: 0
Study 2129373 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute administration of IV beta blocker (metoprolol)
Number of subjects: 0
Study 2129373 — intervention group
Group type: COMPARATOR
Intervention: Delayed administration of beta blocker (starting on Day 6)
Number of subjects: 0
Study 7404301 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg doxycycline and 2 g tinidazole (single preoperative dose)
Number of subjects: 145
Study 7404301 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg gentamicin and 600 mg clindamycin (three doses with eight hour intervals, starting one hour preoperatively)
Number of subjects: 145
Study 7404301 — intervention group
Group type: COMPARATOR
Intervention: No antimicrobial agent (control group)
Number of subjects: 145
Study 31939919 — intervention group
Group type: EXPERIMENTAL
Intervention: Cliradex (terpinen‐4‐ol) lid scrubs
Number of subjects: 50
Study 31939919 — intervention group
Group type: COMPARATOR
Intervention: Sham lid scrubs
Number of subjects: 50
Study 30981750 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Paesaggi di Prevenzione' program
Number of subjects: 5061
Study 28051876 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 100
Study 28051876 — intervention group
Group type: COMPARATOR
Intervention: Control (no breastfeeding)
Number of subjects: 100
Study 26051455 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of misoprostol
Number of subjects: 95
Study 23812769 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose intraoperative radiation therapy (IORT)
Number of subjects: 0
Study 23812769 — intervention group
Group type: COMPARATOR
Intervention: 6-week whole-breast external-beam radiation therapy (WB-EBRT)
Number of subjects: 0
Study 21471093 — intervention group
Group type: EXPERIMENTAL
Intervention: Home testing with CPAP for 3 months
Number of subjects: 296
Study 21471093 — intervention group
Group type: COMPARATOR
Intervention: In-laboratory testing with CPAP for 3 months
Number of subjects: 296
Study 19545475 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg)
Number of subjects: 15
Study 19545475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 16707395 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg daily for 2 weeks
Number of subjects: 12
Study 16707395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16291351 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol inhalation
Number of subjects: 41
Study 16291351 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 41
Study 12122921 — intervention group
Group type: EXPERIMENTAL
Intervention: NK1 receptor antagonists
Number of subjects: 0
Study 12122921 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10532692 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (n = 8)
Number of subjects: 16
Study 10532692 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 16
Study 7593698 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal-based toothpaste
Number of subjects: 70
Study 7593698 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentifrice
Number of subjects: 70
Study 2284219 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 4 mg twice daily for 14 days
Number of subjects: 45
Study 2284219 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 4 mg, indomethacin 50 mg, or placebo twice daily for 29 days
Number of subjects: 45
Study 2284219 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 50 mg twice daily for 29 days
Number of subjects: 45
Study 2284219 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily for 29 days
Number of subjects: 45
Study 7457801 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled mechanical ventilation, relaxation, intravenous anaesthesia, at least 1 1 fluid replacement, careful monitoring
Number of subjects: 13
Study 7457801 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 13
Study 30025940 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (ice packs applied after surgery)
Number of subjects: 169
Study 26970404 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole (single-dose)
Number of subjects: 20
Study 26677665 — intervention group
Group type: EXPERIMENTAL
Intervention: SGRS Chinese herbs as adjuvant therapy
Number of subjects: 84
Study 26677665 — intervention group
Group type: COMPARATOR
Intervention: Controlled ovarian hyperstimulation (COH) and IVF‐ET
Number of subjects: 84
Study 23013325 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal alcohol exposure
Number of subjects: 480
Study 23013325 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-to-moderate levels of alcohol exposure
Number of subjects: 480
Study 23013325 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly alcohol consumption by mothers
Number of subjects: 480
Study 23013325 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol abuse/dependence with ≥ 4 drinks/occasion
Number of subjects: 480
Study 23013325 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower prepregnancy weight of mothers
Number of subjects: 480
Study 22198102 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 100 mg aspirin and 200 mg cilostazol
Number of subjects: 54
Study 18204334 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (2 mg/d, titrated to a maximum of 30 mg/d at day 28)
Number of subjects: 295
Study 18204334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study 18204334 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 295
Study 16311188 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic device flexing and extending the left knee at 30 degrees/s, 60 degrees/s, and 120 degrees/s
Number of subjects: 25
Study 16311188 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective dorsal rhizotomy
Number of subjects: 25
Study 12562459 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint oil (90 mg)
Number of subjects: 12
Study 12562459 — intervention group
Group type: EXPERIMENTAL
Intervention: Caraway oil (50 mg)
Number of subjects: 12
Study 12562459 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg)
Number of subjects: 12
Study 12562459 — intervention group
Group type: EXPERIMENTAL
Intervention: n-butylscopolamine (10 mg)
Number of subjects: 12
Study 12562459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12